Company intelligence / Profile preview

Telum Therapeutics

Pamplona, Navarra, Spaintelumtherapeutics.com ↗

Ownership: Private
Employees: ~21
Development stage: Preclinical

Overview

Telum Therapeutics leverages bacteriophage biology from unexplored soil metagenomes to develop unique libraries of phages and engineer their lytic enzymes into potent antibacterial agents. Their technology uses modular enzyme structures allowing synthetic recombination for enhanced activity or broader spectrum targeting. The approach aims at overcoming antibiotic resistance by providing new enzybiotic therapies[1][2][4][5].

Therapeutic areas: Infectious Diseases
Modalities: Engineered Phage Lytic Proteins (Enzybiotics)Engineered phage lysins combining enzymatic hydrolysis and substrate recognition domainsSynthetic biology-based engineered proteins with enhanced antimicrobial activity
Industry: Biotech

Drug pipeline

1 asset

Telum Therapeutics VRE EPLE

Preclinical

Beyond the preview

Go deeper on Telum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telum Therapeutics.

Explore the full profile